Adefovir Dipivoxil reduces Liver HBV DNA to <0.1 pg of viral DNA per mg of total DNA (pg/mg) in transgenic mice expressing hepatitis B virus. Adefovir Dipivoxil treatment also reduces serum HBV DNA to 3.5 log10 genomic equivalents (ge)/mL in transgenic mice expressing hepatitis B virus compared to 5.3 log10 ge/mL for the placebo control group. Adefovir Dipivoxil antiviral activity reaches near maximum viral reduction by day 10 in the liver and reaches an endpoint of liver virus inhibition at 1.0 mg/kg/day. Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.
| Molecular Weight | 501.47 |
| Formula | C20H32N5O8P |
| CAS Number | 142340-99-6 |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Reverse Transcriptase Products |
|---|
| Fosalvudine tidoxil
Fosalvudine tidoxil is an orally active nucleoside reverse transcriptase inhibitor (NRTI). |
| Emtricitabine triphosphate tetrasodium salt
Emtricitabine triphosphate tetrasodium salt is the tetrasodium salt form of Emtricitabine triphosphate and a nucleoside reverse transcriptase inhibitor (NRTI) targeting HIV and HBV. |
| M-MLV Reverse transcriptase
M-MLV Reverse transcriptase (M-MLV RT) is a kind of Reverse transcriptase, from the moroni mouse leukemia virus (MoMLV). |
| ddUTP
ddUTP (2′,3′-Dideoxyuridine-5′-triphosphate) is a selective HIV and AMV reverse transcriptase inhibitor with Ki values of 0.05 µM and 1 µM, respectively. |
| Rovafovir etalafenamide
Rovafovir etalafenamide (GS-9131), a proagent of the adenosine nucleotide analogue GS-9148, is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Rovafovir etalafenamide is potent and active against a variety of NRTI mutants, and shows potent anti-HIV-1 activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
